Brief: C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-In-Class Profile At The International Myeloma Society Annual Meeting
20/09/2025 16:14
Sept 20 (Reuters) - C4 Therapeutics Inc CCCC.O: C4 THERAPEUTICS PRESENTS CEMSIDOMIDE PHASE 1 MULTIPLE MYELOMA DATA SUPPORTING POTENTIAL BEST-IN-CLASS PROFILE AT THE INTERNATIONAL MYELOMA SOCIETY ANNUAL MEETING Source text: ID:nGNX84SdSy Further company coverage: CCCC.O ((Reuters.Briefs@thomsonreuters.com;))